Atea reports Q2 net loss $32.9M; HCV Phase 3 C-BEYOND hits primary endpoint

Atea Pharmaceuticals, Inc.

Net loss $32.9M ($0.41/sh) vs $37.2M ($0.44/sh) in Q2 2025; cash & investments $219.5M, down from $301.8M at year-end 2025.
C-BEYOND met primary non-inferiority endpoint: BEM/RZR SVR 93.9% vs SOF/VEL 94.8% in mITT (n=905); SVR 93.5% in non-cirrhotics with 8-week regimen.
C-FORWARD enrollment completed (880+ patients, 17 countries); topline expected early Q1 2027; NDA submission anticipated Q2 2027.
AT-587 Phase 1 trial initiated in July 2026 for hepatitis E virus; no approved HEV therapy exists.
R&D expenses $28.2M in Q2 2026, down from $32.3M year-over-year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.